Urticaria Pigmentosa (Mastocytosis, Mastocytoma) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Urticaria Pigmentosa (Mastocytosis, Mastocytoma) – Drugs In Development, 2024 report and make more profitable business decisions.
Urticaria pigmentosa, or mastocytosis of the skin, is a condition characterized by a rash of reddish-brown spots called mastocytomas. These are accumulations of mast cells that have the same genetic mutation, one of several potential mutations in the KIT gene. Symptoms include itching, hives, wheezing, diarrhea and anaphylaxis. Diagnosing doctors look for Darier sign (raised bumps due to rubbing skin patches) and suggest skin biopsy and blood tests. Bone marrow biopsy may be suggested in adults. Avoiding histamine release triggers like insect bites and stings, exposure to extreme temperature, and rubbing the skin can be helpful. Medications like antihistamines can be used to relieve the symptoms.
The Urticaria Pigmentosa (Mastocytosis, Mastocytoma) drugs in development market research report provide comprehensive information on the therapeutics under development for Urticaria Pigmentosa (Mastocytosis, Mastocytoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Urticaria Pigmentosa (Mastocytosis, Mastocytoma) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Urticaria Pigmentosa (Mastocytosis, Mastocytoma) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 7 molecules, with 6 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Urticaria Pigmentosa (Mastocytosis, Mastocytoma) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Urticaria Pigmentosa (Mastocytosis, Mastocytoma) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Urticaria Pigmentosa (Mastocytosis, Mastocytoma) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
KeifeRx LLCMedical University of Vienna
Merck & Co Inc
NemaGen Discoveries Inc
Novelty Nobility Inc
Sixal Inc
Valcrest Pharmaceuticals LLC
Table of Contents
Table
Figures
Frequently asked questions